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Background. Regadenoson is a selective A2A adenosine receptor agonist indicated for
radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise
stress. However, the safety, tolerability, and plasma concentrations associated with repeated
doses have not previously been assessed.
Method and Results. Healthy males and females were randomized to receive intravenous
regadenoson [100 lg (3 doses), 200 lg (3 doses), or 400 lg (2 doses)], or placebo (2 or 3 doses; 0.9%
sodium chloride); all doses 10 minutes apart. The primary endpoint was vital sign measurements
(blood pressure and heart rate). Secondary endpoints included 12-lead electrocardiogram mea-
surements, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and adverse
events. Thirty-six subjects were randomized and completed the study. Plasma concentrations of
regadenoson increased in a dose-related manner and with successive doses. No consistent effect
was observed for systolic blood pressure, although diastolic blood pressurewas slightly lower than
placebo for all regadenoson groups. Transient, dose-dependent increases in heart rate were
observed in all regadenoson groups. There were no serious adverse events; 27 adverse events
occurred in 14 regadenoson-treated subjects vs two events in two placebo-treated subjects.
Conclusion. Repeated doses of regadenoson appeared to be safe and well tolerated in healthy
subjects. (J Nucl Cardiol 2017;24:57–65.)




BMI Body mass index
IV Intravenous
MPI Myocardial perfusion imaging
SD Standard deviation
INTRODUCTION
Patients who are unable to perform adequate exer-
cise stress for myocardial perfusion imaging (MPI) are
generally administered a pharmacologic stress agent
such as adenosine, dipyridamole, or regadenoson.1
Adenosine and regadenoson exert dilatory effects on
the coronary vasculature via activation of the A2A
adenosine receptor, but adenosine can also cause
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unwanted systemic vascular and hemodynamic effects
primarily via activation of other adenosine receptor
subtypes. Regadenoson is a selective A2A adenosine
receptor agonist indicated for radionuclide MPI in
patients unable to undergo adequate exercise stress.2 In
phase 3 clinical studies, single doses of regadenoson
were found to be equally efficacious as adenosine.3,4
The safety and tolerability of regadenoson have also
been confirmed in various special populations of
patients, including those with kidney, liver and airway
diseases.5-9
During intravenous (IV) administration, regadeno-
son may infiltrate into subcutaneous tissues in the arm,
thus requiring cessation of delivery and the possibility of
repeating the procedure. The safety and tolerability of
repeat consecutive doses of regadenoson, as well as the
associated plasma concentrations, have not been sys-
tematically assessed. In the present study, we evaluated
these parameters in healthy supine subjects after IV
bolus doses of 100, 200, and 400 lg repeated up to three
times at 10-minute intervals.
The study will provide information on the safety
and tolerability of re-dosing regadenoson.
METHODS
This was a randomized, double-blind, dose escalation,
parallel-group, placebo-controlled, repeat dose-tolerance clin-
ical study of regadenoson in healthy, nonsmoking subjects
performed in the United States between May and August 2013
(ClinicalTrials.gov identifier, NCT01918995). The study was
approved by an institutional review board and was conducted
in accordance with Good Clinical Practice and International
Conference on Harmonization guidelines.10
Subjects
Eligible subjects were healthy men and women, aged 18-
60 years with a body weight of C45 kg and body mass index
between 18 and 32 kg/m2, both inclusive; Fridericia-corrected
QT interval of B430 msec (males) or B450 msec (females);
and normal aspartate aminotransferase, alanine aminotrans-
ferase, and total bilirubin levels. Female subjects of
childbearing potential were required to use highly effective
birth control from Screening through 28 days after the end of
the study, and male subjects were required to use highly
effective contraception from Screening through 90 days after
final study drug administration. Exclusion criteria included a
history of unexplained syncope, cardiac arrest, unexplained
cardiac arrhythmia or torsade de pointes, structural heart
disease, or family history of either short or long QT syndrome;
a positive result for hepatitis B surface antigen, hepatitis C
antibodies at screening or known human immunodeficiency
virus infection; known or suspected allergy to regadenoson or
any of the components of the trial products, or a history of
multiple and/or severe allergies to drugs or foods, or a history
of severe anaphylactic reactions; a history of smoking within
6 months prior to first dose of regadenoson; treatment with any
prescribed or nonprescribed drugs in the 2 weeks prior to day 1
(except occasional use of acetaminophen, B2 g/day); partic-
ipation in any interventional clinical study or treatment with
any investigational drugs within 30 days or five half-lives,
whichever was longer, prior to screening; participation in a
prior study with regadenoson; or history of consuming more
than 14 units of alcoholic beverages per week within 6 months
prior to screening or history of alcoholism or drug/chemi-
cal/substance abuse within past 2 years prior to screening or a
positive test at screening or 1 day prior to study start for
alcohol or drugs of abuse.
Study Design and Assessments
Subjects were randomized to receive IV regadenoson
[100 lg (3 doses), 200 lg (3 doses), or 400 lg (2 doses)] or
placebo (2 or 3 doses; 0.9% sodium chloride) at a ratio of 3:1
(regadenoson to placebo) for each group. Subjects were
required to abstain from eating and drinking (except water)
for 8 hours prior to drug administration. Subjects received
each dose (over approximately 10 s) in a supine position
administered 10 minutes apart followed by a 5 mL 0.9% saline
flush. The first cohort (9 regadenoson, 3 placebo) started with
the lowest dose of regadenoson, and after a favorable review of
safety, the regadenoson dose was escalated stepwise in
subsequent cohorts.
Blood samples for pharmacokinetic analyses were
obtained prior to study drug administration and at 3, 9, 13,
19, 23, and 29 minutes, and at 1, 2, 4, 8, and 12 hours after the
initial administration. Serial blood pressure and heart rate
measurements for pharmacodynamic analyses were obtained
prior to dosing, at 1, 3, 5, 7, 9, 11, 13, 17, 19, 21, 23, 25, 27,
and 29 minutes during dosing, and at 0.75, 1, 1.5, 2, 4, 8, 12,
and 24 hours postdose. Using the maximum and/or minimum
values for all post-baseline assessments, hemodynamic effects
were defined using the following criteria: heart rate of
C100 bpm or an increase of[40 bpm; systolic blood pressure
of\90 mm Hg or C200 mm Hg, or decreased by[35 mm Hg,
or increased by C50 mm Hg, or C180 mm Hg at baseline and
an increase of C20 mm Hg; diastolic blood pressure of
\50 mm Hg or C115 mm Hg, or decreased by[25 mm Hg,
or increased by C30 mm Hg.
The primary endpoint of the study was safety as evaluated
by vital signs (blood pressure and heart rate). Secondary
endpoints included 12-lead electrocardiogram (ECG) measure-
ments, clinical laboratory evaluations (hematology, chemistry,
and urinalysis), and adverse events (AEs). Plasma concentra-
tions of regadenoson were included as an exploratory endpoint.
Bioanalysis
Frozen plasma samples, containing sodium heparin as the
anticoagulant, were shipped to Worldwide Clinical Trials
(Austin, TX, USA) for analysis using a validated LC-MS/MS
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method. Regadenoson was measured over the calibration range
0.1-40 ng/mL using a 0.2 mL plasma sample volume and a
stable isotope-labeled internal standard (d3-regadenoson).
Sample purification used Strata-X (Phenomenex, Torrance,
CA, USA) 10 mg solid phase extraction 96-well plates
followed by chromatographic separation on a Luna C18(2)
3 lm 2 9 20 mm HPLC column (Phenomenex, Torrance,
CA). The elution profile was a gradient of acetonitrile and
water-containing formic acid. A Sciex API5000 (Applied
Biosystems, Foster City, CA, USA) mass spectrometer was
used to monitor the mass transitions (m/z) 391 ? 259
(regadenoson) and 394 ? 262 (internal standard) in positive
TurboIonSprayTM mode. The mean bias and precision of each
quality control level was within -6.3% to -1.4%, and 1.1% to
3.4%, respectively, over the four analytic runs of this study.
Statistical Analysis
A sample size of 36 subjects (regadenoson, 9 per treatment
group; placebo, 3 per treatment group) was selected. Three
analysis sets were used; the safety analysis set (all subjects who
were randomized and received C1 dose of study drug), the
pharmacokinetic analysis set (all subjects in the safety analysis
set who had C1 quantifiable concentration, and for whom no
major clinical study protocol deviation that was thought to have
interfered with the distribution, metabolism, and excretion of the
compound measured had been reported), and the pharmacody-
namic analysis set (all subjects in the safety analysis set who
provided C1 blood pressure or heart rate measurement postdose
on day 1; subjects with missed doses or protocol violations were
assessed on a subject-by-subject basis for inclusion). Pharma-
cokinetic and pharmacodynamic data were assessed using
descriptive statistics (mean ± standard deviation).
Figure 1. Subject disposition flow diagram.














Male 6 (66.7) 4 (44.4) 4 (44.4) 6 (66.7) 20 (55.6)
Female 3 (33.3) 5 (55.6) 5 (55.6) 3 (33.3) 16 (44.4)
Race [n (%)]
White 1 (11.1) 8 (88.9) 2 (22.2) 4 (44.4) 15 (41.7)
Black or African
American
7 (77.8) 1 (11.1) 7 (77.8) 5 (55.6) 20 (55.6)
Asian 1 (11.1) 0 0 0 1 (2.8)
Ethnicity [n (%)]
Hispanic or Latino 1 (11.1) 3 (33.3) 2 (22.2) 2 (22.2) 8 (22.2)
Non-Hispanic or Latino 8 (88.9) 6 (66.7) 7 (77.8) 7 (77.8) 28 (77.8)
Age (years)
Mean (SD) 36.1 (8.0) 38.3 (11.2) 43.2 (11.3) 32.7 (10.6) 37.7 (10.7)
Range 21–51 25–56 26–60 22–58 21–60
Height (cm)
Mean (SD) 172.4 (8.6) 171.2 (10.9) 170.6 (11.2) 170.1 (12.7) 171.1 (10.5)
Range 155–186 158–186 157–183 156–195 155–195
Weight (kg)
Mean (SD) 77.9 (15.8) 69.8 (10.3) 79.5 (13.5) 73.1 (14.8) 75.1 (13.7)
Range 60.8–106.3 52.1–86.2 58.1–95.1 47.7–87.3 47.7–106.3
BMI (kg/m2)
Mean (SD) 26.0 (3.5) 23.7 (1.9) 27.2 (3.1) 25.1 (3.6) 25.5 (3.2)
Range 21.3–31.9 20.9–26.3 22.2–31.6 19.6–30.8 19.6–31.9
BMI body mass index, SD standard deviation
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RESULTS
Subject Disposition and Demographics
In total, 36 subjects were randomized and all
completed the study (Figure 1). Twenty (55.6%) subjects
were male, and the mean age of all subjects was
37.7 years (Table 1). A greater percentage of black or
African American subjects were randomized to the
placebo group, whereas the regadenoson groups included
similar percentages of black or African American sub-
jects and white subjects. One subject each in the 200- and
400-lg regadenoson groups discontinued treatment after
the first planned dose (see Adverse events, below). These
subjects presented quantifiable plasma concentrations up
to 4 and 8 hours, respectively, but because they did not
receive the subsequent planned doses, plasma concen-
trations measured more than 9 minutes after the initial
dose (i.e., after the second planned dose) were excluded
from the summary statistics, and data from both subjects
were excluded from the pharmacodynamics analysis set.
Pharmacodynamic Results
Overall, there was no consistent pattern of effects
on systolic blood pressure associated with repeat-dose
administration of regadenoson (Figure 2A, Appendix
Table 5). Although the mean systolic blood pressure for
the 200-lg group remained slightly elevated compared
with placebo, this appeared to reflect a higher baseline
value for this group (121.6 mm Hg vs 112.1 mm Hg,
respectively), and no consistent differences with placebo
were observed for the 100-lg and 400-lg groups.
Repeat dosing with regadenoson was associated with
small reductions in diastolic blood pressure (in general,
mean change of\10 mm Hg) (Figure 2B, Appendix
Table 5).
Transient dose-dependent increases in heart rate
occurred following administration of each dose of
regadenoson (Figure 3, Appendix Table 6). At 1 minute
postdose (i.e., the first measured time), the mean heart
rate was increased in the 100-lg group (increase of 28-
31 bpm), 200-lg group (increase of 32-42 bpm), and the
400-lg group (increase of 45-51 bpm).
Categorical hemodynamic effects for blood pressure
and heart rate were predefined (see ‘‘Methods’’ section).
There was no obvious dose-dependence for effects on
systolic or diastolic blood pressure in the categorical
assessment, although effects on heart rate were more
frequently observed with higher doses (Table 2). No
subject in the placebo group met any of the predefined
criteria for hemodynamic effects.
A
B
Figure 2. Mean observed blood pressure up to 1 hour
postdose. (A) Systolic blood pressure; (B) diastolic blood
pressure.
Figure 3. Mean observed heart rate up to 1 hour postdose.
60 Townsend et al. Journal of Nuclear Cardiology
Safety and tolerability of intravenous regadenoson in healthy subjects January/February 2017
Regadenoson Concentration-Time Profiles
The mean plasma concentration-time profiles of
regadenoson obtained are shown in Figure 4A, B (Ap-
pendix Table 7). In each of the 100-, 200-, and 400-lg
groups, the mean concentrations reached a rapid peak
after administration of each dose followed by a relatively
slower decline. The mean peak concentrations increased
in a dose-related manner and increased slightly with each
successive dose. After 12 hours, plasma levels fell below
the level of quantification for all subjects in the 100-lg
group, for four subjects in the 200-lg group, and for three
subjects in the 400-lg group.
Adverse Events
A total of 27 AEs were reported for 14 subjects
receiving regadenoson (51.9%), whereas two AEs were
reported for two subjects receiving placebo (22.2%)
(Table 3). Fourteen AEs were reported for eight (88.9%)
subjects in the 400-lg group, 13 AEs were reported for
six (66.7%) subjects in the 200-lg group, and no AEs
were reported in the 100-lg group. Headache, nausea,
dizziness, sweating, and feeling hot were the most
commonly reported AEs occurring in C5% of the total
subjects receiving regadenoson. All AEs were considered
by investigators to be mild or moderate in severity.
There were no serious AEs or deaths, and no
clinically significant findings were observed in ECGs or
clinical laboratory assessments. Two subjects discontin-
ued treatment after the first study dose of regadenoson.
One subject in the 400-lg group withdrew consent to
Table 2. Blood pressure and heart rates for subjects with hemodynamic effects
Parameter/ criteria [n (%)] Placebo n 5 9
Regadenoson
100 lg n 5 9 200 lg n 5 8 400 lg n 5 8
Systolic blood pressure
\90 mm Hg 0 3 (33.3) 0 0
C200 mm Hg 0 0 0 0
Decrease[35 mm Hg 0 2 (22.2) 1 (12.5) 0
Increase C115 mm Hg 0 0 0 0
C80 and increase C20 mm Hg 0 0 0 0
Diastolic blood pressure
\50 mm Hg 0 1 (11.1) 0 1 (12.5)
C115 mm Hg 0 0 0 0
Decrease[25 mm Hg 0 1 (11.1) 1 (12.5) 0
Increase C30 mm Hg 0 0 0 0
Heart rate
C100 bpm 0 3 (33.3) 7 (87.5) 6 (75.0)
Increase[40 bpm 0 2 (22.2) 4 (50.0) 7 (87.5)
All data from the pharmacodynamic population
A
B
Figure 4. Mean plasma regadenoson concentration-time pro-
files over 60 min (A) and 12 h (B).
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receive further treatment due to anxiety and palpitations.
One subject in the 200-lg group met the protocol-
defined criteria for discontinuation of decreased systolic
blood pressure (two consecutive measurements of
\100 mm Hg). When the incidence of AEs was
assessed following each sequential dose, there was no
obvious pattern of their occurrence with respect to each
dose (Table 4).
Table 3. Reported adverse events*













Any adverse event 2 (22.2) 0 6 (66.7) 8 (88.9) 14 (51.9)
Adverse events leading to study drug
discontinuation
0 0 0 1 (11.1) 1 (3.7)
Headache 1 (11.1) 0 5 (55.6) 4 (44.4) 9 (33.3)
Nausea 0 0 1 (11.1) 2 (22.2) 3 (11.1)
Dizziness 0 0 1 (11.1) 1 (11.1) 2 (7.4)
Sweating 0 0 1 (11.1) 1 (11.1) 2 (7.4)
Feeling hot 0 0 0 2 (22.2) 2 (7.4)
Palpitations 0 0 0 1 (11.1) 1 (3.7)
Stomach discomfort 0 0 0 1 (11.1) 1 (3.7)
Anxiety 0 0 0 1 (11.1) 1 (3.7)
Dyspnea 0 0 0 1 (11.1) 1 (3.7)
Dysphagia 0 0 1 (11.1) 0 1 (3.7)
Muscular weakness 0 0 1 (11.1) 0 1 (3.7)
Paresthesia 0 0 1 (11.1) 0 1 (3.7)
Somnolence 0 0 1 (11.1) 0 1 (3.7)
Subcutaneous nodule 1 (11.1) 0 0 0 0
* Any adverse event observed after administration of the first dose of study drug or matching placebo until 24 hours after
administration of the last dose of study drug or matching placebo
Table 4. Reported adverse events following each dose
Event following Placebo n 5 9
Regadenoson
100 lg n 5 9 200 lg n 5 9 400 lg n 5 9
Dose 1 [n (%)], E 0 0 4 (44.4), 7 5 (55.6), 9
AE 2 headache 2 feeling hot
1 paraesthesia 1 dyspnoea
1 dizziness 1 hyperhidrosis
1 dysphagia 1 anxiety
1 nausea 1 palpitations
1 hyperhidrosis 1 dizziness
1 headache
1 nausea
Dose 2 [n (%)], E 1 (11.1), 1 0 4 (44.4), 4 4 (44.4), 5
AE 1 headache 2 headache 3 headache
1 somnolence 1 stomach discomfort
1 muscular weakness 1 nausea
Dose 3 [n (%)], E 1 (11.1), 1 0 1 (11.1), 2 NA
AE 1 subcutaneous nodule 1 headache
N number of subjects, E number of events, NA not applicable
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DISCUSSION
This study demonstrated that, following repeated IV
administration of regadenoson at doses of 100, 200, or
400 lg, the heart rate was transiently increased, whereas
the diastolic blood pressure was slightly lower than with
placebo. Although the dose-related effect on heart rate
paralleled the measurable plasma concentration, the
effect on diastolic blood pressure was not clearly dose
dependent, and no consistent effect was evident on
systolic blood pressure in these subjects. Repeated doses
were well tolerated in these subjects, as AEs were not
experienced by subjects in the 100-lg group and no
unexpected AEs were reported in the 200- and 400-lg
groups.
The increases in heart rate in this study were
greater than those observed in the phase 3 clinical
studies, perhaps owing to factors such as the younger
age and lack of cardiovascular disease in the healthy
subjects included in this study. Differences in the
responses of heart rate and blood pressure following
administration of regadenoson may provide further
support for the idea that A2A receptor agonists may
exert effects on the sympathetic nervous system that
are separable from effects on vascular baroreceptors.
For example, intracerebral administration of a selective
A2A receptor agonist in rats was shown to increase
heart rate without any accompanying effect on blood
pressure.11 In a separate study, the increased heart rate
in rats treated with regadenoson was shown to be
inhibited by metoprolol (a b blocker), whereas rega-
denoson-mediated effects on blood pressure were
unaffected.12 Since some AEs such as chest pain and
dyspnea associated with adenosine have also been
observed with regadenoson (albeit at a lower inci-
dence), it had been proposed that these effects might be
due at least in part to sympathetic stimulation rather
than activation of different adenosine receptor sub-
types.4 An indirect effect via sympathetic nerves may
also help to explain the lack of clear dose-relatedness
in blood pressure responses, because sympathetic
activity would also be subject to regulation via multiple
other receptors.
The study is limited by the relatively small
sample size in each treatment group, which limits
the conclusions that can be drawn. For example, it is
possible that dose-related effects on blood pressure
may have been more evident with larger study groups.
Moreover, the results in healthy subjects cannot
necessarily be extrapolated to patients for whom
MPI would be indicated. Nevertheless, the efficacy,
safety, and tolerability of single doses of regadenoson
have been demonstrated to be independent of various
baseline factors in patients who require MPI.3 Based
on the current data, there is no reason to believe that
these factors would necessarily differ with repeated
doses.
Importantly, the observed plasma concentration and
pharmacodynamic effects of repeated doses of regade-
noson in this study were predictable based on these
parameters in single-dose studies.3,4,13 Given the con-
sistency of safety and tolerability also between single
and repeated doses, this study may further support the
use of regadenoson for MPI in subjects unable to
undergo exercise stress.
New Knowledge Gained
In healthy subjects, doses of regadenoson repeated
up to three times (100 or 200 lg) or two times (400 lg)
at 10-minute intervals produce dose-related increases
in regadenoson plasma concentrations and heart rate.
Systolic blood pressure fell by 9-11 mmHg following
each dose of regadenoson 100 lg and increased by 8-
9 mmHg following each dose of regadenoson 400 lg.
These repeated doses appeared to be safe and consis-
tent with the known adverse event profile of
regadenoson.
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Table 5. Mean (SD) observed systolic blood pressure (SBP) and diastolic blood pressure (DBP) up to 1




Mean mm Hg (SD)
Regadenoson
100 lg
Mean mm Hg (SD)
Regadenoson
200 lg
Mean mm Hg (SD)
Regadenoson
400 lg
Mean mm Hg (SD)
SBP DBP SBP DBP SBP DBP SBP DBP
0 112.1 (9.2) 72.7 (7.1) 118.7 (9.1) 71.4 (9.0) 121.6 (10.2) 74.9 (13.5) 113.4 (7.1) 66.5 (8.4)
1 119.8 (11.1) 75.0 (5.9) 110.1 (18.5) 69.2 (9.5) 128.0 (9.4) 70.3 (7.5) 121.1 (11.9) 68.0 (8.5)
3 119.1 (9.8) 75.2 (6.9) 112.1 (9.9) 67.9 (7.4) 124.4 (7.0) 68.0 (8.6) 118.5 (9.5) 66.1 (6.7)
5 116.0 (8.7) 73.1 (6.3) 113.4 (9.7) 69.2 (7.6) 123.6 (8.0) 71.1 (7.2) 118.9 (10.4) 67.6 (8.4)
7 115.1 (8.8) 75.1 (6.1) 115.0 (11.9) 67.8 (8.0) 123.1 (4.9) 70.4 (7.7) 116.8 (9.8) 66.4 (7.9)
9 114.6 (7.3) 75.4 (7.5) 112.3 (11.8) 69.0 (5.5) 120.8 (5.2) 69.5 (7.9) 117.9 (8.9) 64.4 (9.1)
11 114.9 (10.5) 73.6 (6.3) 108.6 (17.1) 65.1 (11.4) 118.4 (12.1) 68.4 (6.3) 122.4 (16.9) 65.6 (9.9)
13 114.8 (8.0) 75.4 (5.6) 115.7 (11.4) 68.3 (6.5) 123.6 (8.5) 71.8 (9.8) 125.1 (13.0) 67.6 (10.1)
15 117.8 (5.9) 74.7 (7.0) 113.4 (11.3) 68.6 (6.1) 124.1 (7.6) 71.9 (8.3) 123.4 (10.4) 67.8 (10.7)
17 116.8 (7.6) 73.9 (6.5) 112.6 (7.3) 69.1 (5.9) 126.0 (8.5) 70.1 (7.9) 122.5 (11.0) 67.1 (9.3)
19 116.2 (8.1) 73.9 (5.1) 113.9 (10.0) 69.1 (6.0) 124.8 (8.3) 70.1 (8.5) 122.1 (10.5) 67.3 (8.1)
21 114.2 (6.1) 75.0 (5.5) 107.8 (16.2) 66.9 (9.8) 123.3 (6.1) 68.4 (7.2) 119.9 (11.7) 66.5 (9.0)
23 113.8 (6.0) 75.1 (4.0) 114.3 (11.2) 69.4 (7.4) 126.8 (6.2) 70.0 (9.7) 120.4 (8.2) 66.1 (7.0)
25 112.6 (7.4) 74.8 (4.7) 113.3 (7.9) 68.8 (8.2) 125.6 (6.0) 71.4 (9.3) 120.3 (11.1) 66.6 (8.6)
27 113.6 (7.7) 72.3 (4.7) 114.4 (8.8) 67.3 (6.6) 126.5 (7.0) 70.4 (8.5) 116.5 (8.6) 65.6 (8.6)
29 112.4 (6.8) 73.3 (5.2) 110.2 (6.9) 70.2 (8.9) 127.4 (8.3) 70.3 (8.1) 116.8 (11.0) 64.3 (7.3)
45 111.6 (7.6) 74.0 (6.6) 109.0 (7.3) 68.6 (7.4) 124.5 (7.6) 72.8 (11.0) 108.9 (8.7) 65.4 (4.9)
60 109.7 (9.0) 72.1 (7.0) 107.1 (5.7) 67.2 (5.9) 122.6 (7.4) 69.4 (7.8) 107.4 (8.7) 62.8 (6.8)


















0 61.3 (12.1) 60.4 (12.3) 63.9 (10.1) 60.4 (14.7)
1 64.8 (11.2) 88.0 (8.1) 96.4 (16.7) 105.6 (17.2)
3 62.4 (9.6) 75.2 (14.0) 87.5 (18.3) 98.5 (16.7)
5 60.7 (9.0) 70.6 (12.2) 81.4 (13.5) 91.6 (14.1)
7 63.8 (10.9) 68.0 (13.3) 78.0 (11.5) 87.0 (16.3)
9 63.2 (10.2) 66.9 (13.1) 75.6 (12.0) 84.3 (13.5)
11 62.3 (10.3) 88.6 (10.7) 99.3 (13.3) 111.1 (19.1)
13 63.1 (8.0) 77.8 (15.3) 90.9 (13.5) 104.3 (17.3)
15 61.0 (9.4) 76.0 (16.1) 86.8 (11.5) 98.5 (19.8)
17 61.6 (9.8) 72.3 (14.0) 85.1 (12.8) 92.9 (17.0)
19 62.6 (8.1) 71.3 (14.4) 83.8 (11.3) 89.6 (18.0)
21 61.1 (10.0) 91.7 (9.5) 104.9 (10.7) 87.6 (17.3)
23 62.6 (11.1) 78.8 (13.7) 96.3 (13.0) 87.0 (15.5)
25 60.8 (9.9) 74.6 (13.0) 93.1 (10.1) 85.1 (18.6)
27 60.3 (9.4) 72.0 (11.9) 87.6 (11.2) 84.0 (14.3)
29 60.6 (10.4) 72.3 (14.3) 87.6 (8.4) 82.4 (15.7)
45 60.2 (10.5) 65.6 (11.3) 76.9 (11.0) 74.8 (13.6)
60 61.4 (12.2) 63.6 (11.1) 74.5 (11.3) 69.6 (12.3)
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0 0 (0) 0 (0) 0 (0)
3 4.909 (1.177) 9.048 (2.554) 17.948 (6.205)
9 2.001 (0.275) 4.103 (0.627) 8.567 (1.416)
13 6.334 (1.249) 10.486 (2.663) 23.991 (5.493)
19 3.132 (0.419) 6.235 (1.033) 13.370 (2.314)
23 7.346 (1.199) 13.005 (3.628) 10.233 (2.192)
29 3.928 (0.624) 7.829 (1.295) 7.284 (1.650)
60 1.552 (0.342) 3.478 (0.936) 4.024 (1.370)
120 0.936 (0.240) 1.939 (0.376) 2.455 (0.663)
240 0.470 (0.124) 0.956 (0.156) 1.208 (0.302)
480 0.076 (0.075) 0.291 (0.096) 0.364 (0.084)
720 0 (0) 0.078 (0.066) 0.108 (0.070)
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